DNL 151
Alternative Names: BIIB-122; DNL-151Latest Information Update: 01 Oct 2024
At a glance
- Originator Genentech
- Developer Biogen; Denali Therapeutics Inc
- Class Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Parkinson's disease